This historical review highlights the variability in clinical response to early angina treatments and the significant placebo effect observed in clinical practice.
Variability in angina responses warrants cautious trial interpretation; leaves open placebo mechanisms for prospective study.
BEGINNING with the preparation of theobromine sodium salicylate in 18941 and erythrol tetra-nitrate in 1895,2 many new measures have been advocated for the prevention of attacks of angina pectoris. The efficacy of each has been substantiated, apparently, by sound theoretical considerations, good laboratory results, impressive clinical evidence or combinations of all three. In clinical practice, however, the physician finds that the excellent clinical response in some patients is contrasted by questionable results or complete failures in others. Furthermore, equally good results have been reported to follow the administration of placebos. Certainly, no therapeutic measure advocated to date can be accepted . . .
No takes yet. Share an insight, caveat, or question.
A 1959 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: